STERIS (NYSE:STE) Issues Earnings Results

STERIS (NYSE:STE) posted its earnings results on Tuesday. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16, RTT News reports. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.89%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $2.00 EPS. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Performance

NYSE:STE traded down $3.70 during trading hours on Friday, hitting $235.98. 421,762 shares of the company were exchanged, compared to its average volume of 488,756. The stock has a market capitalization of $23.33 billion, a price-to-earnings ratio of 61.76 and a beta of 0.83. STERIS has a 52-week low of $195.47 and a 52-week high of $243.37. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. The company’s 50 day moving average price is $225.17 and its 200-day moving average price is $222.88.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, September 5th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Thursday, September 5th. This is an increase from STERIS’s previous quarterly dividend of $0.52. STERIS’s payout ratio is currently 54.45%.

Insiders Place Their Bets

In other STERIS news, VP Renato Tamaro sold 1,154 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total transaction of $267,312.56. Following the sale, the vice president now owns 6,677 shares of the company’s stock, valued at approximately $1,546,660.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other STERIS news, Director Jacqueline B. Kosecoff sold 4,584 shares of STERIS stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $231.53, for a total transaction of $1,061,333.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Renato Tamaro sold 1,154 shares of STERIS stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total transaction of $267,312.56. Following the sale, the vice president now owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,762 shares of company stock valued at $1,798,477. Insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

STE has been the topic of a number of analyst reports. Stephens reaffirmed an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Wednesday. Piper Sandler reaffirmed a “neutral” rating and issued a $225.00 price objective (up previously from $220.00) on shares of STERIS in a research report on Friday, May 10th. StockNews.com downgraded shares of STERIS from a “buy” rating to a “hold” rating in a research report on Monday. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $243.60.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.